TDMS Study 55301-05 Pathology Tables
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
Facility: TSI Mason Research
Chemical CAS #: 110-86-1
Lock Date: 12/15/94
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Natural Death 15 5 14 22
Moribund Sacrifice 3 8 7 2
Survivors
Terminal Sacrifice 32 37 29 26
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (50) (50) (50)
Hyperplasia, Lymphoid 1 (2%)
Parasite Metazoan 3 (6%) 3 (6%) 3 (6%) 1 (2%)
Intestine Large, Rectum (50) (50) (50) (50)
Parasite Metazoan 1 (2%) 2 (4%) 1 (2%) 2 (4%)
Intestine Large, Cecum (50) (50) (50) (50)
Inflammation, Chronic 1 (2%)
Inflammation, Chronic Active 1 (2%)
Parasite Metazoan 1 (2%)
Ulcer 1 (2%)
Intestine Small, Duodenum (50) (50) (50) (50)
Ectopic Pancreas 1 (2%)
Inflammation, Chronic Active 1 (2%)
Intestine Small, Ileum (50) (49) (50) (50)
Hyperplasia, Lymphoid 3 (6%) 2 (4%) 2 (4%) 5 (10%)
Inflammation, Chronic Active 1 (2%)
Liver (50) (50) (50) (50)
Angiectasis 2 (4%) 2 (4%) 3 (6%) 2 (4%)
Basophilic Focus 38 (76%) 28 (56%) 11 (22%)
Clear Cell Focus 4 (8%) 9 (18%) 11 (22%) 16 (32%)
Congestion 4 (8%) 1 (2%) 3 (6%) 2 (4%)
Developmental Malformation 1 (2%) 2 (4%) 1 (2%)
Eosinophilic Focus 19 (38%) 24 (48%) 22 (44%) 15 (30%)
Fibrosis 1 (2%) 1 (2%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%) 2 (4%)
Hemorrhage 1 (2%) 1 (2%)
Hepatodiaphragmatic Nodule 9 (18%) 8 (16%) 3 (6%) 3 (6%)
Inflammation, Chronic Active 9 (18%) 1 (2%) 2 (4%) 4 (8%)
Mitotic Alteration 1 (2%) 1 (2%)
Mixed Cell Focus 2 (4%) 4 (8%) 1 (2%) 5 (10%)
Necrosis 6 (12%) 1 (2%) 1 (2%)
Pigmentation 6 (12%) 2 (4%) 6 (12%) 17 (34%)
Tension Lipidosis 3 (6%) 1 (2%)
Vacuolization Cytoplasmic 10 (20%) 7 (14%) 9 (18%) 18 (36%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Bile Duct, Hyperplasia 20 (40%) 29 (58%) 34 (68%) 29 (58%)
Capsule, Inflammation, Chronic 2 (4%)
Centrilobular, Cytomegaly 1 (2%) 4 (8%) 20 (40%)
Centrilobular, Degeneration 1 (2%) 2 (4%) 2 (4%) 7 (14%)
Centrilobular, Necrosis 1 (2%) 2 (4%) 1 (2%)
Mesentery (9) (11) (7) (12)
Ectopic Spleen 1 (14%)
Inflammation 1 (8%)
Fat, Necrosis 8 (89%) 9 (82%) 6 (86%) 11 (92%)
Oral Mucosa (2) (1) (2)
Pharyngeal, Hyperplasia 1 (50%)
Pharyngeal, Inflammation, Acute 1 (100%)
Pancreas (49) (50) (50) (50)
Atrophy 22 (45%) 14 (28%) 13 (26%) 14 (28%)
Cytoplasmic Alteration 1 (2%)
Ectopic Liver 2 (4%) 2 (4%) 3 (6%)
Hyperplasia 3 (6%) 2 (4%)
Inflammation, Chronic 1 (2%) 2 (4%)
Salivary Glands (50) (50) (50) (50)
Atrophy 2 (4%) 3 (6%) 1 (2%)
Cytoplasmic Alteration 1 (2%) 1 (2%)
Inflammation, Chronic 2 (4%)
Stomach, Forestomach (50) (50) (50) (50)
Fibrosis 1 (2%)
Hyperkeratosis 1 (2%)
Inflammation, Acute 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Inflammation, Chronic Active 2 (4%) 1 (2%) 2 (4%) 1 (2%)
Ulcer 3 (6%) 3 (6%) 4 (8%) 4 (8%)
Epithelium, Hyperplasia, Squamous 2 (4%) 2 (4%) 2 (4%) 1 (2%)
Stomach, Glandular (50) (50) (50) (50)
Erosion 6 (12%) 9 (18%) 9 (18%) 7 (14%)
Inflammation, Chronic 1 (2%)
Inflammation, Chronic Active 1 (2%)
Mineralization 2 (4%)
Ulcer 1 (2%) 1 (2%) 3 (6%)
Tongue (1) (2)
Epithelium, Hyperplasia 1 (100%) 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (49) (50) (50) (50)
Cardiomyopathy 42 (86%) 43 (86%) 43 (86%) 36 (72%)
Inflammation, Chronic Active 1 (2%)
Mineralization 1 (2%)
Thrombosis 2 (4%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Accessory Adrenal Cortical Nodule 1 (2%)
Atrophy 1 (2%)
Congestion 1 (2%) 1 (2%)
Cyst 1 (2%) 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hemorrhage 1 (2%)
Hyperplasia 11 (22%) 12 (24%) 9 (18%) 6 (12%)
Vacuolization Cytoplasmic 6 (12%) 8 (16%) 6 (12%) 3 (6%)
Adrenal Medulla (50) (50) (50) (49)
Hyperplasia 5 (10%) 7 (14%) 8 (16%) 2 (4%)
Necrosis 1 (2%)
Islets, Pancreatic (49) (50) (50) (50)
Hyperplasia 1 (2%) 1 (2%)
Parathyroid Gland (48) (50) (48) (50)
Hyperplasia 1 (2%)
Pituitary Gland (49) (50) (50) (50)
Pigmentation 1 (2%)
Pars Distalis, Angiectasis 11 (22%) 9 (18%) 12 (24%) 4 (8%)
Pars Distalis, Cyst 16 (33%) 18 (36%) 20 (40%) 8 (16%)
Pars Distalis, Ectasia 1 (2%)
Pars Distalis, Hemorrhage 1 (2%)
Pars Distalis, Hyperplasia 22 (45%) 29 (58%) 21 (42%) 18 (36%)
Pars Intermedia, Hyperplasia 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Ultimobranchial Cyst 3 (6%) 1 (2%)
C-Cell, Hyperplasia 16 (32%) 17 (34%) 13 (26%) 10 (20%)
Follicular Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (47) (48) (50) (49)
Hyperplasia 1 (2%) 2 (4%) 1 (2%) 2 (4%)
Inflammation, Acute 1 (2%) 2 (4%)
Inflammation, Chronic 3 (6%) 1 (2%) 5 (10%) 2 (4%)
Inflammation, Chronic Active 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Vacuolization Cytoplasmic 1 (2%)
Bilateral, Inflammation, Acute 1 (2%)
Duct, Ectasia 3 (6%) 5 (10%) 4 (8%) 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Ovary (50) (50) (50) (50)
Congestion 1 (2%)
Cyst 3 (6%) 7 (14%) 4 (8%) 2 (4%)
Hyperplasia 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Pigmentation 1 (2%)
Bilateral, Cyst 1 (2%) 2 (4%)
Uterus (50) (50) (50) (50)
Angiectasis 1 (2%)
Cyst 1 (2%) 1 (2%)
Developmental Malformation 1 (2%)
Dilatation 1 (2%) 1 (2%) 2 (4%)
Hemorrhage 1 (2%) 1 (2%)
Hyperplasia 1 (2%)
Hyperplasia, Cystic 6 (12%) 5 (10%) 7 (14%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Inflammation, Chronic Active 1 (2%)
Metaplasia, Squamous 1 (2%)
Necrosis 1 (2%) 1 (2%)
Cervix, Hypertrophy 1 (2%)
Cervix, Inflammation, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Depletion Cellular 1 (2%) 2 (4%) 2 (4%)
Fibrosis 1 (2%) 1 (2%)
Hyperplasia 3 (6%) 4 (8%) 1 (2%)
Hyperplasia, Reticulum Cell 1 (2%)
Necrosis 1 (2%)
Erythroid Cell, Hyperplasia 1 (2%)
Myeloid Cell, Hyperplasia 1 (2%)
Lymph Node (7) (9) (15) (19)
Iliac, Congestion 2 (29%)
Iliac, Ectasia 2 (11%)
Mediastinal, Congestion 3 (43%) 1 (11%) 4 (27%) 1 (5%)
Mediastinal, Hyperplasia, Lymphoid 1 (7%)
Mediastinal, Pigmentation 1 (14%) 1 (5%)
Pancreatic, Congestion 1 (7%)
Pancreatic, Pigmentation 1 (11%)
Renal, Congestion 1 (14%) 1 (11%) 1 (7%)
Renal, Ectasia 1 (11%) 1 (5%)
Renal, Hyperplasia, Lymphoid 1 (5%)
Lymph Node, Mandibular (49) (50) (50) (50)
Atrophy 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Congestion 1 (2%) 1 (2%)
Ectasia 3 (6%) 4 (8%) 9 (18%) 2 (4%)
Edema 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 1 (2%) 1 (2%)
Hyperplasia, Plasma Cell 1 (2%)
Infiltration Cellular, Plasma Cell 1 (2%)
Necrosis 1 (2%)
Lymph Node, Mesenteric (49) (50) (50) (50)
Congestion 2 (4%) 3 (6%)
Ectasia 4 (8%)
Hemorrhage 1 (2%)
Hyperplasia, Lymphoid 2 (4%) 2 (4%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 1 (2%)
Spleen (50) (50) (50) (50)
Atrophy 1 (2%)
Congestion 1 (2%) 2 (4%)
Fibrosis 2 (4%) 3 (6%) 3 (6%) 4 (8%)
Hematopoietic Cell Proliferation 2 (4%) 4 (8%) 2 (4%)
Hemorrhage 2 (4%)
Metaplasia, Osseous 1 (2%)
Necrosis 1 (2%) 2 (4%) 1 (2%)
Pigmentation 1 (2%)
Capsule, Inflammation, Chronic 1 (2%)
Thymus (50) (50) (50) (50)
Congestion 1 (2%)
Cyst 1 (2%)
Ectopic Parathyroid Gland 2 (4%) 1 (2%) 1 (2%) 2 (4%)
Fibrosis 1 (2%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Galactocele 3 (6%) 5 (10%) 1 (2%)
Hyperplasia 5 (10%) 2 (4%) 6 (12%) 5 (10%)
Inflammation, Chronic Active 1 (2%)
Duct, Dilatation 13 (26%) 9 (18%) 13 (26%) 13 (26%)
Skin (50) (50) (50) (50)
Hyperkeratosis 2 (4%)
Hyperplasia, Squamous 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Inflammation, Acute 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%)
Inflammation, Chronic Active 2 (4%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibrosis 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteopetrosis 9 (18%) 12 (24%) 10 (20%) 5 (10%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Hemorrhage 1 (2%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Congestion 1 (2%)
Hemorrhage 1 (2%)
Infiltration Cellular, Histiocyte 13 (26%) 10 (20%) 9 (18%) 11 (22%)
Inflammation, Chronic 9 (18%) 8 (16%) 6 (12%) 8 (16%)
Bronchiole, Alveolus, Hyperplasia 1 (2%)
Nose (50) (50) (50) (50)
Congestion 1 (2%)
Cyst 1 (2%) 1 (2%)
Hemorrhage 1 (2%)
Inflammation, Chronic 2 (4%) 3 (6%)
Inflammation, Chronic Active 15 (30%) 15 (30%) 16 (32%) 19 (38%)
Nasolacrimal Duct, Cyst 2 (4%)
Nasolacrimal Duct, Inflammation, Chronic
Active 1 (2%) 1 (2%)
Respiratory Epithelium, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (2)
Hemorrhage 1 (100%) 2 (100%)
Harderian Gland (1)
Inflammation, Chronic 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Accumulation, Hyaline Droplet 1 (2%)
Congestion 2 (4%) 1 (2%)
Cyst 1 (2%)
Hydronephrosis 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Inflammation, Acute 1 (2%)
Mineralization 3 (6%) 4 (8%) 6 (12%)
Nephropathy 41 (82%) 42 (84%) 35 (70%) 37 (74%)
Pigmentation 2 (4%) 1 (2%)
Renal Tubule, Hyperplasia 1 (2%)
Urinary Bladder (50) (50) (50) (50)
Hemorrhage 1 (2%)
Inflammation, Chronic 3 (6%) 1 (2%) 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Moribund Sacrifice 11 13 15 10
Natural Death 14 17 10 24
Survivors
Terminal Sacrifice 25 20 25 16
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (48) (50) (49)
Hyperplasia, Lymphoid 1 (2%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 1 (2%)
Parasite Metazoan 4 (8%) 4 (8%) 3 (6%) 2 (4%)
Intestine Large, Rectum (50) (48) (50) (49)
Edema 1 (2%)
Parasite Metazoan 4 (8%) 2 (4%) 1 (2%)
Intestine Large, Cecum (49) (47) (50) (49)
Edema 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
Inflammation, Acute 1 (2%) 1 (2%) 1 (2%)
Inflammation, Chronic Active 1 (2%)
Parasite Metazoan 1 (2%) 1 (2%)
Ulcer 1 (2%)
Intestine Small, Duodenum (50) (47) (50) (48)
Ectopic Pancreas 1 (2%)
Intestine Small, Jejunum (50) (47) (50) (47)
Congestion 1 (2%)
Intestine Small, Ileum (50) (47) (50) (47)
Fibrosis 1 (2%)
Hyperplasia, Lymphoid 6 (12%) 9 (19%) 3 (6%) 4 (9%)
Liver (50) (49) (50) (50)
Angiectasis 1 (2%) 1 (2%) 1 (2%)
Basophilic Focus 12 (24%) 5 (10%) 1 (2%)
Clear Cell Focus 7 (14%) 1 (2%) 7 (14%) 4 (8%)
Congestion 1 (2%)
Degeneration, Cystic 4 (8%) 12 (24%) 11 (22%) 3 (6%)
Developmental Malformation 1 (2%) 1 (2%)
Eosinophilic Focus 14 (28%) 23 (47%) 23 (46%) 13 (26%)
Fibrosis 1 (2%) 1 (2%) 1 (2%) 10 (20%)
Hematopoietic Cell Proliferation 2 (4%) 1 (2%)
Hepatodiaphragmatic Nodule 3 (6%) 1 (2%)
Mitotic Alteration 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Mixed Cell Focus 2 (4%) 1 (2%) 3 (6%) 1 (2%)
Necrosis 2 (4%) 1 (2%) 1 (2%) 2 (4%)
Pigmentation 4 (8%) 11 (22%) 20 (40%) 25 (50%)
Thrombosis 1 (2%)
Vacuolization Cytoplasmic 4 (8%) 6 (12%) 13 (26%) 17 (34%)
Bile Duct, Hyperplasia 46 (92%) 43 (88%) 44 (88%) 49 (98%)
Centrilobular, Cytomegaly 4 (8%) 8 (16%) 6 (12%)
Centrilobular, Degeneration 1 (2%) 3 (6%) 2 (4%) 8 (16%)
Centrilobular, Necrosis 3 (6%) 5 (10%)
Periportal, Fibrosis 2 (4%) 29 (58%)
Mesentery (11) (14) (7) (8)
Cyst 1 (9%)
Hemorrhage 1 (14%)
Inflammation, Acute 1 (7%)
Fat, Necrosis 10 (91%) 13 (93%) 6 (86%) 8 (100%)
Oral Mucosa (1) (2)
Pharyngeal, Hyperplasia 1 (50%)
Pancreas (50) (48) (50) (49)
Atrophy 18 (36%) 15 (31%) 17 (34%) 12 (24%)
Cytoplasmic Alteration 2 (4%)
Hyperplasia 2 (4%) 4 (8%) 2 (4%) 3 (6%)
Inflammation, Chronic 1 (2%) 3 (6%)
Acinus, Hyperplasia 1 (2%)
Artery, Inflammation, Acute 1 (2%)
Salivary Glands (50) (50) (50) (50)
Cellular Alteration 1 (2%)
Inflammation, Chronic Active 1 (2%)
Stomach, Forestomach (50) (49) (50) (49)
Hyperkeratosis 2 (4%)
Inflammation, Acute 1 (2%) 1 (2%)
Inflammation, Chronic Active 2 (4%) 8 (16%)
Ulcer 2 (4%) 10 (20%) 3 (6%) 4 (8%)
Epithelium, Hyperplasia, Squamous 1 (2%) 7 (14%) 7 (14%) 11 (22%)
Stomach, Glandular (50) (49) (50) (49)
Erosion 15 (30%) 17 (35%) 12 (24%) 12 (24%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Mineralization 2 (4%) 2 (4%) 8 (16%)
Necrosis 1 (2%)
Ulcer 2 (4%) 5 (10%) 1 (2%) 1 (2%)
Tooth (2) (1) (1)
Dysplasia 1 (100%)
Inflammation, Acute 1 (50%)
Inflammation, Chronic Active 1 (50%) 1 (100%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Cardiomyopathy 45 (90%) 43 (86%) 43 (86%) 46 (92%)
Mineralization 1 (2%) 3 (6%) 2 (4%)
Thrombosis 2 (4%) 6 (12%) 3 (6%) 4 (8%)
Coronary Artery, Inflammation, Chronic Active 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (50) (50)
Accessory Adrenal Cortical Nodule 1 (2%) 1 (2%)
Congestion 1 (2%)
Hyperplasia 8 (16%) 7 (14%) 7 (14%) 2 (4%)
Hypertrophy 1 (2%) 2 (4%)
Vacuolization Cytoplasmic 9 (18%) 5 (10%) 9 (18%) 7 (14%)
Adrenal Medulla (50) (49) (50) (49)
Hyperplasia 17 (34%) 22 (45%) 19 (38%) 15 (31%)
Bilateral, Hyperplasia 1 (2%) 1 (2%) 1 (2%)
Islets, Pancreatic (50) (48) (50) (49)
Hyperplasia 5 (10%) 2 (4%) 1 (2%) 1 (2%)
Parathyroid Gland (50) (50) (50) (48)
Hyperplasia 1 (2%) 3 (6%) 3 (6%)
Pituitary Gland (50) (50) (50) (50)
Pars Distalis, Angiectasis 2 (4%) 2 (4%) 2 (4%)
Pars Distalis, Cyst 2 (4%) 8 (16%) 3 (6%) 1 (2%)
Pars Distalis, Degeneration 1 (2%)
Pars Distalis, Ectasia 1 (2%)
Pars Distalis, Hemorrhage 1 (2%)
Pars Distalis, Hyperplasia 22 (44%) 16 (32%) 18 (36%) 12 (24%)
Pars Distalis, Thrombosis 1 (2%)
Thyroid Gland (50) (50) (50) (49)
Pigmentation 1 (2%)
Ultimobranchial Cyst 1 (2%) 1 (2%) 1 (2%)
C-Cell, Hyperplasia 7 (14%) 5 (10%) 3 (6%) 3 (6%)
Follicle, Dilatation 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Follicular Cell, Hyperplasia 1 (2%) 5 (10%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (49) (49) (48)
Fibrosis 1 (2%)
Inflammation, Chronic 2 (4%)
Penis (1)
Inflammation, Chronic Active 1 (100%)
Preputial Gland (50) (47) (49) (48)
Atrophy 1 (2%)
Hyperplasia 4 (8%) 3 (6%) 5 (10%) 4 (8%)
Inflammation, Acute 2 (4%) 2 (4%)
Inflammation, Chronic 17 (34%) 25 (53%) 17 (35%) 23 (48%)
Inflammation, Chronic Active 5 (10%) 14 (30%) 14 (29%) 5 (10%)
Duct, Dilatation 2 (4%) 2 (4%)
Prostate (50) (48) (50) (49)
Hemorrhage, Chronic 1 (2%)
Hyperplasia, Focal 1 (2%) 1 (2%) 4 (8%) 2 (4%)
Inflammation, Acute 2 (4%) 2 (4%) 1 (2%)
Inflammation, Chronic 2 (4%) 1 (2%) 4 (8%) 3 (6%)
Inflammation, Chronic Active 31 (62%) 29 (60%) 24 (48%) 22 (45%)
Seminal Vesicle (50) (47) (50) (48)
Dilatation 1 (2%)
Fibrosis 1 (2%)
Inflammation, Acute 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Inflammation, Chronic Active 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Mineralization 1 (2%)
Testes (49) (49) (49) (48)
Atrophy 2 (4%)
Necrosis 1 (2%)
Thrombosis 1 (2%)
Bilateral, Interstitial Cell, Hyperplasia 3 (6%) 2 (4%) 3 (6%) 1 (2%)
Interstitial Cell, Hyperplasia 9 (18%) 6 (12%) 6 (12%) 4 (8%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Depletion Cellular 2 (4%) 4 (8%) 3 (6%) 1 (2%)
Fibrosis 1 (2%) 1 (2%)
Hemorrhage 1 (2%)
Lymph Node (20) (25) (20) (23)
Iliac, Hyperplasia, Lymphoid 1 (5%) 1 (4%)
Iliac, Infiltration Cellular, Plasma Cell 1 (5%)
Mediastinal, Congestion 5 (20%) 4 (17%)
Mediastinal, Ectasia 1 (5%)
Mediastinal, Hemorrhage 1 (5%) 1 (4%) 2 (10%)
Mediastinal, Hyperplasia, Lymphoid 1 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Mediastinal, Pigmentation 1 (5%)
Pancreatic, Congestion 1 (5%) 2 (9%)
Pancreatic, Edema 1 (4%)
Pancreatic, Hyperplasia, Lymphoid 1 (5%)
Pancreatic, Inflammation, Chronic Active 1 (4%)
Pancreatic, Necrosis 1 (5%)
Pancreatic, Pigmentation 1 (5%)
Renal, Congestion 1 (5%) 1 (5%) 3 (13%)
Renal, Edema 1 (5%)
Renal, Fibrosis 1 (4%)
Renal, Hyperplasia, Lymphoid 2 (10%)
Renal, Pigmentation 1 (5%) 4 (17%)
Lymph Node, Mandibular (50) (50) (50) (50)
Congestion 1 (2%) 1 (2%)
Ectasia 4 (8%) 3 (6%) 2 (4%) 3 (6%)
Hyperplasia, Lymphoid 1 (2%)
Inflammation, Chronic Active 1 (2%)
Lymph Node, Mesenteric (50) (47) (50) (48)
Congestion 2 (4%) 1 (2%)
Ectasia 2 (4%) 3 (6%) 2 (4%) 1 (2%)
Fibrosis 2 (4%)
Hemorrhage 1 (2%) 1 (2%)
Inflammation, Acute 1 (2%)
Necrosis 3 (6%)
Spleen (49) (48) (50) (49)
Atrophy 1 (2%)
Congestion 1 (2%) 1 (2%)
Fibrosis 14 (29%) 11 (23%) 9 (18%) 12 (24%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%) 1 (2%)
Hyperplasia, Focal 1 (2%)
Necrosis 4 (8%) 2 (4%) 1 (2%)
Pigmentation 2 (4%)
Thrombosis 1 (2%)
Thymus (50) (49) (48) (50)
Cyst 1 (2%)
Ectopic Parathyroid Gland 1 (2%)
Fibrosis 1 (2%)
Hemorrhage 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (48) (50) (49)
Concretion 1 (2%)
Galactocele 1 (2%)
Hyperplasia 1 (2%) 3 (6%) 2 (4%) 3 (6%)
Duct, Dilatation 14 (29%) 16 (33%) 12 (24%) 15 (31%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 13
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - CONT
Skin (50) (50) (50) (50)
Cyst Epithelial Inclusion 2 (4%)
Hyperkeratosis 1 (2%)
Hyperplasia, Squamous 1 (2%) 1 (2%)
Inflammation, Acute 1 (2%)
Necrosis 1 (2%)
Epidermis, Degeneration 1 (2%)
Subcutaneous Tissue, Inflammation, Chronic
Active 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Fibrous Osteodystrophy 2 (4%) 1 (2%) 4 (8%) 6 (12%)
Hyperostosis 1 (2%)
Osteomalacia 1 (2%)
Osteopetrosis 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (48) (50)
Hemorrhage 1 (2%)
Hydrocephalus 1 (2%)
Inflammation, Acute 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Congestion 1 (2%) 2 (4%)
Hemorrhage 2 (4%) 2 (4%)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Infiltration Cellular, Histiocyte 6 (12%) 4 (8%) 9 (18%) 9 (18%)
Inflammation, Chronic 8 (16%) 10 (20%) 12 (24%) 9 (18%)
Metaplasia, Osseous 1 (2%)
Alveolar Epithelium, Hyperplasia 3 (6%) 3 (6%)
Nose (50) (50) (49) (50)
Cyst 1 (2%) 1 (2%)
Cyst Epithelial Inclusion 1 (2%)
Inflammation, Chronic 1 (2%)
Inflammation, Chronic Active 26 (52%) 18 (36%) 21 (43%) 25 (50%)
Polyp Inflammatory 1 (2%)
Nasolacrimal Duct, Cyst 1 (2%) 1 (2%)
Nasolacrimal Duct, Inflammation, Acute 1 (2%) 1 (2%)
Squamous Epithelium, Nasolacrimal Duct,
a Number of animals examined microscopically at site and number of animals with lesion
Page 14
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PYRIDINE Date: 10/08/97
Route: DOSED WATER Time: 11:05:00
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1)
Atrophy 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (48) (50) (49)
Atrophy 1 (2%)
Cyst 3 (6%) 3 (6%) 13 (26%) 10 (20%)
Developmental Malformation 2 (4%)
Hydronephrosis 3 (6%) 1 (2%) 2 (4%)
Inflammation, Acute 1 (2%)
Nephropathy 47 (94%) 47 (98%) 49 (98%) 49 (100%)
Pigmentation 1 (2%)
Artery, Inflammation, Acute 1 (2%)
Artery, Inflammation, Chronic Active 1 (2%)
Capsule, Hemorrhage, Chronic 1 (2%)
Pelvis, Inflammation, Acute 1 (2%)
Renal Tubule, Hyperplasia 1 (2%) 4 (8%) 7 (14%)
Urinary Bladder (50) (47) (50) (49)
Hemorrhage 1 (2%) 1 (2%) 1 (2%)
Inflammation, Chronic 4 (8%) 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 15
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------